Sign in
Active, not recruitingPhase 1

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

Key facts

Who runs it
AbbVie
Where
Boston, Chicago, Cincinnati, Louisville, Philadelphia, Pittsburgh, Portland, and Seattle, United StatesSee the 8 sitesAlso in 9 other countries, 27 sites
Status
Active, not recruiting
Phase
Phase 1
People taking part
124 people, planned
Started
24 Jun 2019
Expected to end
Mar 2029
Type of study
Interventional, 5 groups
Treatments tested
  • Upadacitinib
Record updated
3 August 2026

Who can take part

Age
2 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participant have total body weight of 10 kg or higher at the time of screening
  • Participant diagnosed with pcJIA (rheumatoid factor-positive or rheumatoid factor-negative polyarticular JIA, extended oligoarticular JIA, or systemic JIA with active arthritis and without active systemic features) with a history of arthritis affecting at least 5 joints within the first 6 months of disease (for extended oligoarticular JIA: <=4 joints within first 6 months of disease and >4 joints thereafter)
  • Participant have 5 or more active joints at the time of screening, defined as the presence of swollen joints (not due to deformity) or, in the absence of swelling, joints with the limitation of movement (LOM) plus pain on motion and/or tenderness with palpitation, with LOM present in at least three of the active joints
  • If receiving methotrexate (MTX), have been taking MTX for at least 12 weeks immediately before and including Study Day 1 on a stable dose of <=20 mg/m2 for at least 8 weeks before and including Study Day 1; in addition, participants should take either folic acid or folinic acid according to local standard of care
  • If on oral glucocorticosteroids, must have been taking oral glucocorticosteroids at a stable dose (no greater than 10 mg/day or 0.2 mg/kg/day, whatever is lower) for at least 1 week before and including Study Day 1

Who cannot take part

  • Participant have prior exposure to JAK inhibitor
  • Participant with diagnosis of enthesitis-related arthritis (ERA) or juvenile psoriatic arthritis (JPSA)

Where in United States

Also in 9 other countries, 27 sites

  • Boston Children's HospitalBoston, United States
  • Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United States
  • Cincinnati Childrens Hospital Medical CenterCincinnati, United States
  • University of LouisvilleLouisville, United States
  • The Children's Hospital of PhiladelphiaPhiladelphia, United States
  • Children's Hospital of Pittsburgh of UPMCPittsburgh, United States
  • Randall Children's HospitalPortland, United States
  • Seattle Children's HospitalSeattle, United States

About the trial

What the trial wants to find out

This is a study to evaluate pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with polyarticular course juvenile idiopathic arthritis. This study consists of three parts: Part 1 is multiple-cohort study that consists of two sequential multiple dose groups. Participants benefiting from the study drug with no ongoing adverse events of special interest or serious adverse events will have option to enroll in Part 2. Part 2 is open-label, long term extension study to evaluate safety and tolerability. Part 3 is an additional safety cohort to evaluate long-term safety and tolerability. Participants <18 years of age who are ongoing in Parts 2 and 3 will participate in an 104 week open-label extension of the study in Part 4.

The 5 groups in the trial

  • Participants of age group 12 to <18 years receiving dose ATreatment being tested

    Participants of age group 12 to \<18 years administered with upadacitinib dose A (weight dependent) as described in the protocol.

    Treatment: Upadacitinib

  • Participants of age group 12 to <18 years receiving dose BTreatment being tested

    Participants of age group 12 to \<18 years administered with upadacitinib dose B (weight dependent) as described in the protocol.

    Treatment: Upadacitinib

  • Participants of age group 6 to <12 years receiving dose ATreatment being tested

    Participants of age group 6 to \<12 years administered with upadacitinib dose A (weight dependent) as described in the protocol.

    Treatment: Upadacitinib

  • Participants of age group 2 to <6 years receiving dose ATreatment being tested

    Participants of age group 2 to \<6 years administered with upadacitinib dose A (weight dependent) as described in the protocol.

    Treatment: Upadacitinib

  • Participants of age group 2 to <18 years receiving dose ATreatment being tested

    Participants of age group 2 to \<18 years administered with upadacitinib dose A as described in the protocol.

    Treatment: Upadacitinib

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
Record updated
3 August 2026